Anton Hagenbeek
Affiliations: | 1997-2013 | Hematology | Utrecht University, Utrecht, Netherlands |
Website:
https://profs.library.uu.nl/index.php/profrec/getprofdata/769/19/231/0Google:
"Anton Hagenbeek"Parents
Sign in to add mentor| Dirk Willem van Bekkum | grad student | 1977 | Erasmus University | |
| (Extracorporeal irradiation of the blood in a rat leukaemia model.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kersten MJ, Driessen J, Zijlstra JM, et al. (2020) Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Haematologica |
| Rosenwald A, Bens S, Advani R, et al. (2019) Prognostic Significance of Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900743 |
| Morschhauser F, Flinn IW, Advani R, et al. (2019) Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). The Lancet. Haematology |
| Caglayan C, Dixon J, Wall A, et al. (2019) A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group Blood. 134: 2812-2812 |
| Hagenbeek A, Mooij H, Zijlstra J, et al. (2018) Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study. Haematologica |
| Hagenbeek A, Zijlstra JM, Plattel WJ, et al. (2018) Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study Blood. 132: 2923-2923 |
| Stevens WBC, Mendeville M, Redd R, et al. (2017) Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium. Haematologica |
| Younes A, Hilden P, Coiffier B, et al. (2017) International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of Oncology : Official Journal of the European Society For Medical Oncology |
| van Imhoff GW, McMillan A, Matasar MJ, et al. (2016) Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016690198 |
| Shi Q, Flowers CR, Hiddemann W, et al. (2016) Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016708651 |